News & Publications

A Novel AHI-1-BCR-ABL-DNM2 Complex Regulates Leukemic Properties of Primitive CML Cells through Enhanced Cellular Endocytosis and ROS-mediated Autophagy.

Posted May 17, 2017 | Publications

Liu X, Rothe K, Yen R, Fruhstorfer C, Maetzig T, Chen M, Forrest D, Humphries RK & Jiang X.

Leukemia 2017. [Epub ahead of print]



Tyrosine kinase inhibitor (TKI) therapies induce clinical remission with remarkable effects on chronic myeloid leukemia (CML). However, very few TKIs completely eradicate the leukemic clone and persistence of leukemic stem cells (LSCs) remains challenging, warranting new, distinct targets for improved treatments. We demonstrated that the scaffold protein AHI-1 is highly deregulated in LSCs and interacts with multiple proteins, including Dynamin-2 (DNM2), to mediate TKI-resistance of LSCs. We have now demonstrated that the SH3 domain of AHI-1 and the proline rich domain of DNM2 are mainly responsible for this interaction. DNM2 expression was significantly increased in CML stem/progenitor cells; knockdown of DNM2 greatly impaired their survival and sensitized them to TKI treatments. Importantly, a new AHI-1-BCR-ABL-DNM2 protein complex was uncovered, which regulates leukemic properties of these cells through a unique mechanism of cellular endocytosis and ROS-mediated autophagy. Thus, targeting this complex may facilitate eradication of LSCs for curative therapies.Leukemia advance online publication, 21 April 2017; doi:10.1038/leu.2017.108.

See PubMed Link